The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
October 16, 2023
View Complete Issue         Table of Contents 2019 
Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)
October 16, 2023 (Issue: 1687)
The FDA has approved the oral kinase inhibitor quizartinib (Vanflyta – Daiichi Sankyo) for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Quizartinib (Vanflyta) for Acute Myeloid Leukemia (online only)
Article code: 1687d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.